SCHEMBL433533

SCHEMBL433533

Cc1ccc(C=O)cc1OCC(=O)OCCCBr

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.40
FDPS P14324 1/20 0.40
POLB P06746 1/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
TSHR P16473 1/20 0.38
CYP2C9 P11712 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSP90AA1 P07900 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949360 0.85 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2TDP1GAAPOLB
SCHEMBL7829446 0.78 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2TDP1KMT2AL3MBTL1
SCHEMBL435985 0.77 MAOA (0.46) ALDH1A1SMN1; SMN2TDP1KDM4ENPC1
SCHEMBL435132 0.77 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2FDPSPOLBKDM4E
SCHEMBL528365 0.76 POLB (0.48) ALDH1A1SMN1; SMN2TDP1KMT2AGAA
SCHEMBL2008196 0.76 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TDP1L3MBTL1FDPS
SCHEMBL13850149 0.74 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2KMT2AGAAPOLB
SCHEMBL8888441 0.74 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TDP1KMT2AL3MBTL1
SCHEMBL10421723 0.73 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2TDP1KMT2AL3MBTL1
SCHEMBL13858849 0.73 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2TDP1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595665-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE Inspire Pharmaceuticals, Inc. (US) 2013-05-29 EP disclosed
US-20130131106-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE INSPIRE PHARMACEUTICALS, INC. (US) 2013-05-23 US disclosed
WO-2012012282-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE INSPIRE PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131106-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE ROCK2, ROCK1, RHOA ALDH1A1 4514/4885SMN1; SMN2 2784/4885TDP1 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.